Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy
Authors:
- Pascal DumyPDPascal Dumy
- Danièle CarrezDCDanièle Carrez
- Alain CroisyACAlain Croisy
- Martine DemeunynckMDMartine Demeunynck
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (7) , 1990-1994
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Enzyme-Catalyzed Activation of Anticancer ProdrugsPharmacological Reviews, 2004
- Nitroreductase-based GDEPTCurrent Pharmaceutical Design, 2002
- Prodrug strategies in cancer therapyEuropean Journal of Medicinal Chemistry, 2001
- Antibody-directed enzyme prodrug therapy (ADEPT): a reviewAdvanced Drug Delivery Reviews, 1997
- Gene directed enzyme prodrug therapy for cancerAdvanced Drug Delivery Reviews, 1997
- Prodrugs in cancer chemotherapyStem Cells, 1995
- Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12FEMS Microbiology Letters, 1994
- The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)Cancer and Metastasis Reviews, 1993
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—IIBiochemical Pharmacology, 1992
- The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—IBiochemical Pharmacology, 1992